ClinicalTrials.gg
CompletedNCT03497429Updated Nov 9, 2021Results posted

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Niraparib in Advanced Solid Tumors, sponsored by Takeda. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.

Read the detailed description

The drug being tested in this study is called Niraparib. Niraparib is being tested to treat Japanese participants with advanced solid tumors. This study will look at the safety, tolerability and pharmacokinetics of Niraparib administered once daily orally.

The study will enroll approximately 12 participants as a maximum. Participants will be assigned to Cohort 1 (21-day treatment cycle). After that, participants will be assigned to Cohort 2 when safety and tolerability of the 200 mg dose will be demonstrated.

This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 16 months. Participants will make multiple visits to the clinic with final visit approximately 28 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese male or female participants aged 20 years or older on the day of signing .
  2. Participants must have a - or histologically-confirmed or locally advanced solid tumor and have failed or progressed after standard therapy, or for which standard therapy does not exist in the opinion of the investigator.
  3. Participants must have Performance Status of less than or equal to (\<=) 1 on the (ECOG) Performance Status Scale.
  4. Participants must have adequate organ function as indicated by the following laboratory values:

    1. Hematology

      • : greater than or equal to (>=) 1500 per microliter (μL)
      • count: >=100,000/μL
      • : >=9 gram per deciliter (g/dL)
    2. Kidney

      • Serum creatinine: \<=1.5*institutional (ULN), OR of >=50 milliliter per minute (mL/min) (as calculated using the Cockcroft Gault equation or measured using 24-hour urine creatinine clearance) for participants with creatinine levels >=1.5*institutional ULN.
    3. Liver

      • Total in serum: \<=1.5*ULN (except in participants with Gilbert's syndrome). Participants with Gilbert's syndrome may be enrolled if the participant's direct bilirubin is \<=1.5*ULN of the direct bilirubin.
      • (AST) and alanine aminotransferase (ALT): \<=2.5*ULN OR \<=5*ULN if participants have liver metastases.
    4. Coagulation (does not pertain to participants receiving anticoagulants)

      • (PT): \<=1.2*ULN
      • Activated partial thromboplastin time (aPTT): \<=1.2*ULN
  5. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice one highly effective method of and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)

    Male participants, even if surgically sterilized (ie, vasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug. If the female partner of a male participant is of child bearing potential, it should also be advised to use a highly effective method of contraception, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
  6. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Participant who have received chemotherapy, radiotherapy, hormonal or biological therapy within 14 days (within 28 days for anticancer monoclonal antibody, within 42 days for nitrosoureas or mitomycin C) prior to Cycle 1 Day 1. If the participant has residual toxicity from prior chemotherapy treatment, such toxicity must be \<=Grade 1 (NOTE: participants with Grade 2 alopecia may qualify for this study). If bevacizumab had been used in the past, all bevacizumab-related toxicities must have resolved. Participants with prostate cancer may have been treated with luteinizing hormone-releasing hormone (LH-RH) analogs.
  2. Participants who received a known or putative poly (ADP-ribose) polymerase (PARP) inhibitor or other drugs that may inhibit the PARP, either as part of a clinical trial or as standard of care.
  3. Participants who initiated bisphosphonate therapy or are adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Participants on a stable bisphosphonate regimen are eligible and may continue the treatment.
  4. Treatment with any products within 28 days or 5 half-lives (whichever was longer) before Cycle 1 Day 1.
  5. Participants who have symptomatic ascites or a symptomatic pleural effusion. A participant who is treated and clinically stable for these conditions is eligible.
  6. Participants with a known primary central nervous system (CNS) tumor.
  7. Participants with known and/or carcinomatous meningitis are excluded. However, participants with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 30 days prior to Cycle 1 Day 1 defined as: (1) no evidence of new or enlarging CNS metastases, (2) off , or (3) on a stable dose and administration of steroids.
  8. Participants who have a to the components of the study drugs or their analogs.
  9. Participants who are considered to be at high medical risk due to a serious, uncontrolled disease, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days prior to Cycle 1 Day 1) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining .
  10. Participants who have a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the participant's participation throughout the study period, or study participation is not in the best interest of the participant.
  11. Known gastrointestinal (GI) disease or GI surgery that could interfere with the GI absorption of study drug, such as difficulty swallowing capsules and total gastrectomy.
  12. Participants who have a psychiatric disorder that may interfere with the conduct of the trial.
  13. Participant is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the past year) of drug or alcohol abuse.
  14. Participants who are pregnant or breast-feeding, or expecting to conceive or be a father of children within the planned duration of the study.

    NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the study.

  15. Known positive.
  16. Known surface antigen (HBsAg) positive, or known or suspected active virus (HCV) infection.

NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus (HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must have an undetectable HCV viral load.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Cohort 1: Niraparib 200 mg

    Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.

    Drug: Niraparib

  • Experimental
    Cohort 2: Niraparib 300 mg

    Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.

    Drug: Niraparib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03 and defined as any of the following events occurring during Cycle 1 that were considered by investigator to be related with niraparib: Any Grade 5 or 4 hematologic toxicity, except Grade 4 neutropenia less than (\<) 7 days; Grade 3 or 4 neutropenia with fever greater than (\>) 38.5 degree Celsius and/or infection requiring antibiotic/anti-fungal treatment; Any Grade 3, 4,or 5 non-hematologic toxicity except: Grade 3 nausea, vomiting, diarrhea/dehydration occurring in setting of inadequate compliance with supportive care and lasting \<48 hours, Inadequately treated hypersensitivity reactions, Grade 3 acidosis/alkalosis that responded to intervention by improving to less than or equal to (\<=) Grade 2 within 48 hours, Isolated asymptomatic Grade 3 amylase elevation, hypercholesterolemia and hypertriglyceridemia; Any TEAE leading to an interruption of niraparib for \>14 days.

    Time frame: Baseline up to Day 21 in Cycle 1 (Cycle length=21 days)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

  3. Number of Participants With Grade 3 or Higher TEAEs

    TEAEs were graded as per the NCI-CTCAE version 4.03. As per the NCI-CTCAE, Grade 1 (mild, asymptomatic or mild symptoms); Grade 2 (moderate, minimal, local or noninvasive intervention indicated); Grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (life-threatening consequences, urgent intervention indicated); Grade 5 (death related to adverse event \[AE\]).

    Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

  4. Number of Participants With Serious TEAEs

    Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

  5. Number of Participants Who Discontinued Study Drug Due to TEAEs

    Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Niraparib

    Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib

    Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

  3. AUC24:Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib

    Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)

07

Results

Posted Nov 9, 2021

Participant flow

Participants took part in the study at 1 investigative site in Japan from 5 April 2018 to 10 February 2020.

Participant flow — Overall Study
MilestoneCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Started36
Started36
Completed00
Completed00
Not completed36
Withdrew: Progressive disease34
Withdrew: Adverse event02

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLT was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03 and defined as any of the following events occurring during Cycle 1 that were considered by investigator to be related with niraparib: Any Grade 5 or 4 hematologic toxicity, except Grade 4 neutropenia less than (\<) 7 days; Grade 3 or 4 neutropenia with fever greater than (\>) 38.5 degree Celsius and/or infection requiring antibiotic/anti-fungal treatment; Any Grade 3, 4,or 5 non-hematologic toxicity except: Grade 3 nausea, vomiting, diarrhea/dehydration occurring in setting of inadequate compliance with supportive care and lasting \<48 hours, Inadequately treated hypersensitivity reactions, Grade 3 acidosis/alkalosis that responded to intervention by improving to less than or equal to (\<=) Grade 2 within 48 hours, Isolated asymptomatic Grade 3 amylase elevation, hypercholesterolemia and hypertriglyceridemia; Any TEAE leading to an interruption of niraparib for \>14 days.

Time frame:
Baseline up to Day 21 in Cycle 1 (Cycle length=21 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Number of Participants With Dose Limiting Toxicities (DLTs)01
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)36
PrimaryNumber of Participants With Grade 3 or Higher TEAEs

TEAEs were graded as per the NCI-CTCAE version 4.03. As per the NCI-CTCAE, Grade 1 (mild, asymptomatic or mild symptoms); Grade 2 (moderate, minimal, local or noninvasive intervention indicated); Grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (life-threatening consequences, urgent intervention indicated); Grade 5 (death related to adverse event \[AE\]).

Time frame:
From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher TEAEs
ParticipantsCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Number of Participants With Grade 3 or Higher TEAEs16
PrimaryNumber of Participants With Serious TEAEs
Time frame:
From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs
ParticipantsCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Number of Participants With Serious TEAEs01
PrimaryNumber of Participants Who Discontinued Study Drug Due to TEAEs
Time frame:
From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to TEAEs
ParticipantsCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Number of Participants Who Discontinued Study Drug Due to TEAEs02
SecondaryCmax: Maximum Observed Plasma Concentration for Niraparib
Time frame:
Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Niraparib
nanogram per milliliter (ng/mL)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Cycle 1 Day 1442.9 ± 195.09529.6 ± 149.22
Cycle 1 Day 21729.2 ± 387.501167 ± 194.94
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib
Time frame:
Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib
hoursCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Cycle 1 Day 14.000 (1.52 to 4.07)4.035 (2.05 to 10.2)
Cycle 1 Day 213.950 (3.83 to 4.03)2.890 (2.88 to 6.00)
SecondaryAUC24:Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib
Time frame:
Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUC24:Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib
hour*nanogram per milliliter (h*ng/mL)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Cycle 1 Day 14931 ± 2905.06270 ± 2631.2
Cycle 1 Day 2113040 ± 6493.319540 ± 3117.2

Adverse events

Collected over Treatment-emergent adverse events were adverse events that started from the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Niraparib 200 mg0/3 (0%)0/3 (0%)3/3 (100%)
Cohort 2: Niraparib 300 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
PyelonephritisInfections and infestations0/31/6
Most frequent other events
Showing 10 of 46
Most frequent other events
EventCohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mg
Platelet count decreasedInvestigations1/35/6
Aspartate aminotransferase increasedInvestigations0/35/6
NauseaGastrointestinal disorders1/34/6
VomitingGastrointestinal disorders2/32/6
FatigueGeneral disorders2/31/6
Blood alkaline phosphatase increasedInvestigations1/34/6
Decreased appetiteMetabolism and nutrition disorders2/32/6
AnaemiaBlood and lymphatic system disorders0/33/6
Alanine aminotransferase increasedInvestigations0/33/6
Gamma-glutamyltransferase increasedInvestigations0/33/6

Baseline characteristics

The safety analysis set included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Mean53.0 ± 13.7561.3 ± 12.9958.6 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Female134
Male235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
American Indian or Alaska Native000
Asian369
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Japan369
Height
Height(centimeter (cm))Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Mean166.7 ± 2.08164.0 ± 7.64164.9 ± 6.27
Weight
Weight(kilogram (kg))Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Mean65.57 ± 8.97664.23 ± 6.57564.68 ± 6.900
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
Mean23.56 ± 2.61423.89 ± 1.88723.78 ± 1.990
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Cohort 1: Niraparib 200 mgCohort 2: Niraparib 300 mgTotal
0235
1134

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • National Cancer Center Hospital
    Chuo-ku, Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites.)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Feb 2020, 22 months.

Results were first posted in Nov 2021, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 13, 2018
StartActual
Apr 5, 2018
Primary completionActual
Feb 10, 2020
CompletionActual
Feb 10, 2020
Results first posted
Nov 9, 2021
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03497429
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Apr 5, 2018
Primary completion
Feb 10, 2020
Completion
Feb 10, 2020
Results posted
Nov 9, 2021
Last update
Nov 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion